- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02639247
Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor (POLARIS-4)
February 8, 2019 updated by: Gilead Sciences
A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor
The primary objectives of the study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (Vosevi®; SOF/VEL/VOX) fixed-dose combination (FDC) for 12 weeks and of sofosbuvir/velpatasvir (Epclusa®; SOF/VEL) FDC for 12 weeks in direct-acting antiviral (DAA)-experienced adults with chronic hepatitis C virus (HCV) infection with or without cirrhosis who have not received prior treatment with a regimen containing an inhibitor of the HCV NS5A protein.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
333
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Camperdown, New South Wales, Australia
-
Darlinghurst, New South Wales, Australia
-
-
Queensland
-
Herston, Queensland, Australia
-
-
Victoria
-
Clayton, Victoria, Australia
-
Melbourne, Victoria, Australia
-
-
-
-
Alberta
-
Calgary, Alberta, Canada
-
Edmonton, Alberta, Canada
-
-
British Columbia
-
Vancouver, British Columbia, Canada
-
-
Ontario
-
Brampton, Ontario, Canada
-
Ottawa, Ontario, Canada
-
Toronto, Ontario, Canada
-
-
-
-
-
Clermont-Ferrand, France
-
Clichy, France
-
Grenoble, France
-
Lille, France
-
Limoges, France
-
Lyon, France
-
Marseille, France
-
Montpellier, France
-
Nice, France
-
Paris, France
-
Pessac, France
-
Toulouse, France
-
Vandoeuvre-les-Nancy, France
-
Villejuif, France
-
-
-
-
-
Berlin, Germany
-
Bonn, Germany
-
Frankfurt am Main, Germany
-
Hamburg, Germany
-
Hannover, Germany
-
Köln, Germany
-
-
-
-
Auckland
-
Grafton, Auckland, New Zealand
-
-
-
-
-
San Juan, Puerto Rico
-
-
-
-
-
London, United Kingdom
-
Oxford, United Kingdom
-
-
-
-
California
-
Long Beach, California, United States
-
Los Angeles, California, United States
-
Palo Alto, California, United States
-
Pasadena, California, United States
-
Rialto, California, United States
-
San Diego, California, United States
-
San Francisco, California, United States
-
-
Colorado
-
Aurora, Colorado, United States
-
Englewood, Colorado, United States
-
-
District of Columbia
-
Washington, District of Columbia, United States
-
-
Florida
-
Gainesville, Florida, United States
-
Miami, Florida, United States
-
Orlando, Florida, United States
-
Wellington, Florida, United States
-
-
Georgia
-
Atlanta, Georgia, United States
-
Marietta, Georgia, United States
-
-
Illinois
-
Chicago, Illinois, United States
-
-
Indiana
-
Indianapolis, Indiana, United States
-
-
Louisiana
-
Bastrop, Louisiana, United States
-
-
Maryland
-
Baltimore, Maryland, United States
-
Catonsville, Maryland, United States
-
-
Massachusetts
-
Boston, Massachusetts, United States
-
-
Michigan
-
Ann Arbor, Michigan, United States
-
Detroit, Michigan, United States
-
-
Missouri
-
Kansas City, Missouri, United States
-
Saint Louis, Missouri, United States
-
-
New Jersey
-
Hillsborough, New Jersey, United States
-
-
New York
-
New York, New York, United States
-
-
North Carolina
-
Asheville, North Carolina, United States
-
Fayetteville, North Carolina, United States
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
-
Pittsburgh, Pennsylvania, United States
-
-
Rhode Island
-
Providence, Rhode Island, United States
-
-
Tennessee
-
Germantown, Tennessee, United States
-
Nashville, Tennessee, United States
-
-
Texas
-
Houston, Texas, United States
-
San Antonio, Texas, United States
-
-
Utah
-
Murray, Utah, United States
-
-
Virginia
-
Falls Church, Virginia, United States
-
Norfolk, Virginia, United States
-
Richmond, Virginia, United States
-
-
Washington
-
Seattle, Washington, United States
-
-
Wisconsin
-
Madison, Wisconsin, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
- Willing and able to provide written informed consent
- HCV RNA ≥ 10^4 IU/mL at screening
- Chronic HCV infection (≥ 6 months)
- Treatment experienced with a direct acting antiviral medication not including a NS5A Inhibitor for HCV
- Use of protocol specified methods of contraception
Key Exclusion Criteria:
- Current or prior history of clinically significant illness that may interfere with participation in the study
- Screening ECG with clinically significant abnormalities
- Laboratory results outside of acceptable ranges at screening
- Pregnant or nursing female
- Chronic liver disease not caused by HCV
- Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SOF/VEL
SOF/VEL for 12 weeks
|
400/100 mg FDC tablet administered orally once daily without regard to food
Other Names:
|
Experimental: SOF/VEL/VOX
SOF/VEL/VOX for 12 weeks
|
400/100/100 mg FDC tablet administered orally once daily with food
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
Time Frame: Posttreatment Week 12
|
SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ) at 12 weeks after stopping study treatment.
|
Posttreatment Week 12
|
Percentage of Participants Who Permanently Discontinue Study Drug Due to an Adverse Event
Time Frame: Up to 12 weeks
|
Up to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
Time Frame: Posttreatment Weeks 4 and 24
|
SVR4 and SVR24 were defined as HCV RNA < LLOQ at 4 and 24 weeks after stopping study treatment, respectively.
|
Posttreatment Weeks 4 and 24
|
Percentage of Participants With Virologic Failure
Time Frame: Up to Posttreatment Week 24
|
|
Up to Posttreatment Week 24
|
Percentage of Participants With HCV RNA < LLOQ On Treatment
Time Frame: Weeks 1, 2, 4, 8 and 12
|
Weeks 1, 2, 4, 8 and 12
|
|
Change From Baseline in HCV RNA
Time Frame: Weeks 1, 2, 4, 8, and 12
|
Weeks 1, 2, 4, 8, and 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 23, 2015
Primary Completion (Actual)
October 5, 2016
Study Completion (Actual)
January 18, 2017
Study Registration Dates
First Submitted
December 21, 2015
First Submitted That Met QC Criteria
December 21, 2015
First Posted (Estimate)
December 24, 2015
Study Record Updates
Last Update Posted (Actual)
March 5, 2019
Last Update Submitted That Met QC Criteria
February 8, 2019
Last Verified
October 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Disease Attributes
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Hepatitis
- Infections
- Communicable Diseases
- Hepatitis C
- Anti-Infective Agents
- Antiviral Agents
- Sofosbuvir
- Velpatasvir
Other Study ID Numbers
- GS-US-367-1170
- 2015-003167-10 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Qualified external researchers may request IPD for this study after study completion.
For more information, please visit our website at https://www.gilead.com/about/ethics-and-code-of-conduct/policies.
IPD Sharing Time Frame
18 months after study completion
IPD Sharing Access Criteria
A secured external environment with username, password, and RSA code.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C Virus Infection
-
University Health Network, TorontoCompletedChronic Hepatitis C Virus InfectionCanada
-
PharmaEssentiaCompletedChronic Hepatitis C Virus InfectionKorea, Republic of, Taiwan, China
-
Gilead SciencesCompleted
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
-
Hadassah Medical OrganizationUnknownChronic Hepatitis C Virus InfectionIsrael
-
Beni-Suef UniversityCompletedChronic Hepatitis C Virus InfectionEgypt
-
Bristol-Myers SquibbCompletedChronic Hepatitis C Virus Infection | Chronic Hepatitis B Virus InfectionUnited States
-
Humanity and Health Research CentreBeijing 302 HospitalCompletedChronic Hepatitis C InfectionChina
-
Vertex Pharmaceuticals IncorporatedTerminatedChronic Hepatitis C Virus InfectionUnited States, New Zealand
Clinical Trials on SOF/VEL/VOX
-
Gilead SciencesTerminatedHepatitis C Virus InfectionPoland, Italy, United Kingdom
-
Gilead SciencesCompletedHepatitis C Virus InfectionUnited States, France, United Kingdom, Germany, Australia, Canada, New Zealand, Puerto Rico
-
Johns Hopkins UniversityCompletedHIV | Liver Disease | HCV CoinfectionUnited States
-
Gilead SciencesCompletedHepatitis CUnited States, France, United Kingdom, Germany, Canada, Australia, New Zealand, Puerto Rico
-
Gilead SciencesCompletedHepatitis C Virus InfectionGermany, United States, Australia, United Kingdom, Canada, France, New Zealand
-
Gilead SciencesCompleted
-
Gilead SciencesTerminatedHepatitis C Virus InfectionFrance, Spain, United States, Australia, Canada, Germany, United Kingdom, Italy, New Zealand, Puerto Rico
-
Gilead SciencesCompletedHepatitis CUnited States, France, United Kingdom, Germany, Australia, Canada, New Zealand, Puerto Rico
-
Gilead SciencesCompleted
-
Gilead SciencesCompletedChronic Hepatitis CNew Zealand